Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction—A Prospective Trial
Therapeutic drug monitoring (TDM) during induction therapy with anti-tumor necrosis factor drugs has emerged as a strategy to optimize response to these biologics and avoid undesired outcomes related to inadequate drug exposure. This study aimed to describe clinical, biological, and endoscopic remis...
Main Authors: | Karoline Soares Garcia, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Luísa Leite Barros, Jane Oba, Carlos Walter Sobrado Junior, Aytan Miranda Sipahi, Olívia Duarte de Castro Alves, Tomás Navarro-Rodriguez, Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Liliana Andrade Chebli, Cristina Flores, Andrea Vieira, Christianne Damasceno Arcelino do Ceará, Natália Sousa Freitas Queiroz, Aderson Omar Mourão Cintra Damião |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/6/1757 |
Similar Items
-
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
by: Yoon Suk Jung, et al.
Published: (2021-01-01) -
Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01) -
Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
by: Yoo Min Lee, et al.
Published: (2024-05-01) -
Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease
by: Kouzhu Zhu, et al.
Published: (2024-08-01) -
Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
by: Jihye Park, et al.
Published: (2023-05-01)